Login

Theravance Biopharma, Inc. SEC Filings

Filed On Filing
05 Oct 2026 15-12G
28 Sep 2026 Form 4: Weiss Asset Management Lp, Former 10% Owner and 2 others

Disposed of 7,457,060 shares (Other Transaction) ($127M)

25 Sep 2026 SCHEDULE 13D/A
24 Sep 2026 Form 4: Miller Aine, SVP, DEV & HEAD OF IRE OFFICE

Returned 189,826 shares to the issuer · Disposed of 37,500 Share Option (Right to Buy) (Disposition to Issuer)

24 Sep 2026 Form 4: Grimaud Brett A., SVP, GEN COUNSEL AND SECRETARY

Returned 355,168 shares to the issuer

24 Sep 2026 Form 4: Sawaf Aziz, SVP & CHIEF FINANCIAL OFFICER

Returned 336,841 shares to the issuer

24 Sep 2026 Form 4: Farnum Rhonda, SVP, COMM & MEDICAL AFFAIRS

Returned 213,476 shares to the issuer · Disposed of 150,000 Share Option (Right to Buy) (Disposition to Issuer)

24 Sep 2026 Form 4: Gray Susannah, Director

Returned 48,146 shares to the issuer · Disposed of 115,942 Share Option (Right to Buy) (Disposition to Issuer)

24 Sep 2026 Form 4: O'Connor Donal, Director

Returned 80,213 shares to the issuer · Disposed of 135,276 Share Option (Right to Buy) (Disposition to Issuer)

24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 S-8 POS
24 Sep 2026 Form 4: Smaldone Alsup Laurie, Director

Returned 80,989 shares to the issuer · Disposed of 148,776 Share Option (Right to Buy) (Disposition to Issuer)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support